New Sydney laboratory expands 360biolabs’ Australian network, bringing established scientific expertise and sample-critical capabilities closer to clinical research in New South Wales.

360biolabs, a BioAgilytix company, has opened a new laboratory in Sydney, bringing its established bioanalytical expertise to New South Wales.

Founded in Melbourne in 2015 by Alistair Draffan, Melinda Pryor and Angela Luttick, 360biolabs was established with a vision to build world-class bioanalytical expertise supported by the rigorous quality systems needed to advance clinical research. Draffan, now President, brought extensive pharmaceutical R&D and scientific operations experience, while Pryor, Executive Vice President of Scientific Operations, brought more than 25 years of expertise in virology and immunology, and Luttick, Executive Vice President of Commercial, extensive experience in drug discovery, development and commercialisation.

Over the past decade, the company has grown from a pioneering Melbourne start-up into a trusted bioanalytical partner with laboratories across Australia and, since joining BioAgilytix in 2021, access to a global laboratory network with laboratories in the US, and EU.

The new 360biolabs facility in North Ryde is strategically located within one of Sydney’s vibrant science and medtech hubs, Macquarie Park Innovation District, alongside a growing community of innovative companies and research organisations.

360biolabs’ strategic expansion reflects its bench-to-bedside philosophy, placing scientific expertise within established research and clinical precincts to support collaboration between academia, industry and clinicians.

Purpose-designed to support both current and future requirements, the facility features state-of-the-art laboratory and office spaces constructed to exacting standards. The laboratories incorporate robust quality and operational systems for containment, security, IT infrastructure, and reliable service delivery.

“The Sydney laboratory marks the next stage of growth for 360biolabs in Australia,” said Alistair Draffan, President. “New South Wales has a strong and growing clinical research sector, and establishing a permanent presence in Sydney allows us to invest alongside that growth. It expands our ability to support clients locally, strengthens our national business and creates a stronger foundation for continued growth in the region.”

The Sydney facility has achieved accreditation from Australia’s National Association of Testing Authorities (NATA) for compliance with ISO/IEC 17025 and operates under the same rigorous procedures, policies and quality standards as 360biolabs’ three other facilities across Australia.

The laboratory encompasses significant BSL-2 space supporting PBMC isolation and flow cytometry, with separate dedicated laboratories for sample reception and storage in a 24/7 temperature-monitored facility, including ULT freezer and vapor phase nitrogen cryostorage. These capabilities support time-sensitive clinical samples where proximity, processing speed and scientific oversight are critical.

“Across 360biolabs, each of our laboratories has assay development capability, supported by the expertise and collaboration of our broader scientific network. Our Sydney team members have worked with 360biolabs for several years, bringing assay development and validation expertise and a shared scientific culture. This supports continuity from development through to sample analysis, with our scientists and instrumentation aligned to deliver reliable results for our clients,” said Melinda Pryor, Executive Vice President, Scientific Operations.

As a BioAgilytix company, 360biolabs’ reach also extends beyond Australia. Global sponsors choosing Australia for early-phase clinical development can have assays established at 360biolabs and transferred under quality systems and harmonised SOPs to BioAgilytix laboratories in the US or Europe.

This combination of local knowledge and global reach provides sponsors with continuity from early-phase clinical development in Australia through to later-stage global programs.